Prostate cancer is a leading malignancy among men worldwide and an increasing challenge for emerging economies. The expanded BRICS nations represent regions undergoing rapid demographic and epidemiological transitions, yet data on their comparative disease and economic burden remain limited.

Residual lesions after transurethral resection of bladder tumor (TURBT) are a major contributor to recurrence in bladder cancer. Advances in diagnostic technology are shifting postoperative management from conventional macroscopic evaluation toward molecular-level assessment.

Chemotherapy-induced neutropenia (CIN) may reflect higher pharmacodynamic exposure and relate to improved outcomes, but its clinical relevance in pancreatic cancer remains uncertain.

This meta-analysis sought to assess the efficacy and safety of poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) as maintenance therapy for patients with newly diagnosed advanced ovarian cancer (OC).

Non-muscle invasive bladder cancer (NMIBC) is a malignancy with a significant recurrence and progression risk. While intravesical Bacillus Calmette-Guérin (BCG) has remained the standard of care for decades, limitations in efficacy, tolerability, and global supply underscore the need for novel therapeutic strategies. Many patients relapse after BCG and are offered radical cystectomy, a highly morbid operation which some are unfit for or decline. Immune checkpoint inhibitors (ICIs) have revolutionized neoadjuvant and advanced bladder cancer therapy. This has driven interest in ICIs as bladder-sparing alternatives in BCG-unresponsive high-risk NMIBC (HR-NMIBC).

Intravesical sequential gemcitabine - docetaxel (Gem/Doce) has emerged as an important chemotherapeutic regimen in the management of non - muscle-invasive bladder cancer (NMIBC). It holds particular clinical significance in the context of high-risk NMIBC (HR-NMIBC) that either fails standard Bacillus Calmette - Guérin (BCG) immunotherapy or when BCG is contraindicated or unavailable. The combination leverages two cytotoxic agents with complementary mechanisms to achieve tumor eradication while aiming to preserve the bladder.

Patients with advanced EGFR-mutant NSCLC and high PD-L1 expression (TPS ≥50%) typically respond poorly to EGFR-TKI monotherapy. We compared EGFR-TKI plus chemotherapy versus TKI alone in this population.

Neuroendocrine neoplasms (NENs) of the lung make up a heterogeneous clinicopathologic ensemble, encompassing well-differentiated neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Despite being characterized since decades, they still continue to embody diagnostic and therapeutic challenges, where establishing correlations among tumor nomenclature, molecular alterations, and therapeutic options is essential for the best clinical decision making.

This subgroup analysis investigates the clinical characteristics, treatment patterns, and outcomes of chronic lymphocytic leukemia (CLL) in the Middle East (ME).

Urothelial carcinoma (UC) is a highly aggressive malignancy that has traditionally been treated with platinum-based chemotherapy. In recent years, the therapeutic landscape has undergone substantial transformation with the advent of precision oncology, particularly through the introduction of immune checkpoint inhibitors, targeted agents, and antibody-drug conjugates (ADCs).

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have markedly improved clinical outcomes and are the preferred first-line treatment for metastatic hormone receptor - positive breast cancer. However, acquired resistance is almost universal, leading to a critical need for effective strategies in the post-CDK4/6i setting.

Targeted therapy is an established treatment strategy for biliary tract cancer (BTC), yet its clinical efficacy remains limited when compared to promising and findings. This highlights the translational gap between preclinical research and real-world patient outcomes, emphasizing the urgent need for improved strategies to bridge laboratory insights with clinical practice.

Peritoneal recurrence challenges pediatric solid tumors. HIPEC is established in adults but pediatric evidence is limited. We assessed safety and preliminary efficacy of intraoperative HIPEC in children.

Lung cancer remains the leading cause of cancer-related mortality, and reliable prognostic biomarkers are needed. The prognostic significance of myeloid-derived suppressor cells (MDSCs) in lung cancer is the aim of the current systematic review and meta-analysis.

To explore Ubiquitin D (UBD) and autophagy in hepatocellular carcinoma (HCC) and the key role of Olaparib targeting UBD in treating HCC.

This review critically appraises recent clinical and translational advances on ropeginterferon alfa-2b, a long-acting, mono-pegylated interferon that has become a key therapeutic option for polycythemia vera (PV). Beyond its cytoreductive efficacy, ropeginterferon exerts immunomodulatory and antiproliferative effects that may modify disease biology. The review outlines its therapeutic rationale, pharmacologic profile, and emerging role as a disease-modifying agent compared with conventional cytoreductive therapies.

Oncolytic viruses (OVs) are a promising yet understudied class of therapeutic agents. OVs mediate anti-tumor activity through multiple mechanisms, including direct lysis of tumor cells, local expression of therapeutic transgenes, and induction of anti-tumor immunity. In 2015, Talimogene laherparepvec (T-VEC) was approved OV for melanoma. Recent literature search and real-world experience have highlighted some of the challenges with clinical adoption of OV therapy and identified new opportunities for improving the clinical use of OVs for cancer treatment.

To investigate the impact of baseline and temporal changes of the CT-body compositions on survival in patients with colorectal liver metastases (CLRM) undergoing intra-arterial treatment.

Neuroplasticity is a dynamic process by which the brain reorganizes its structure and function in response to internal and external stimuli. In patients with brain neoplasms, neuroplasticity is crucial for preserving or restoring function, as it enables compensation for the tumor-induced disruption of neuronal circuits. Understanding this adaptive capacity is vital for improving clinical outcomes.

This systematic review and meta-analysis evaluated whether compression therapy prevents chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients receiving taxanes.